<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Advances in Molecular Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Advances in Molecular Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Успехи молекулярной онкологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-805X</issn><issn publication-format="electronic">2413-3787</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">392</article-id><article-id pub-id-type="doi">10.17650/2313-805X-2021-8-4-75-83</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Study of the effect of curcumin on excision DNA repair in U251 glioblastoma multiforme cells</article-title><trans-title-group xml:lang="ru"><trans-title>Изучение действия куркумина на эксцизионную репарацию ДНК в клетках U251 мультиформной глиобластомы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9626-6847</contrib-id><name-alternatives><name xml:lang="en"><surname>Kushnir</surname><given-names>T. I.</given-names></name><name xml:lang="ru"><surname>Кушнир</surname><given-names>Т. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Bld. 15, 24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0154-8604</contrib-id><name-alternatives><name xml:lang="en"><surname>Arnotskaya</surname><given-names>N. E.</given-names></name><name xml:lang="ru"><surname>Арноцкая</surname><given-names>Н. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Bld. 15, 24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7588-1066</contrib-id><name-alternatives><name xml:lang="en"><surname>Kudryavtsev</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Кудрявцев</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Bld. 15, 24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4125-7342</contrib-id><name-alternatives><name xml:lang="en"><surname>Mitrofanov</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Митрофанов</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Bld. 15, 24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4160-9598</contrib-id><name-alternatives><name xml:lang="en"><surname>Bekyashev</surname><given-names>A. K.</given-names></name><name xml:lang="ru"><surname>Бекяшев</surname><given-names>А. Х.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Bld. 15, 24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4532-4274</contrib-id><name-alternatives><name xml:lang="en"><surname>Zgoda</surname><given-names>V. G.</given-names></name><name xml:lang="ru"><surname>Згода</surname><given-names>В. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>10 Bld. 8, Pogodinskaya St., Moscow 119121</p></bio><bio xml:lang="ru"><p>119121 Москва, Погодинская ул., 10, стр. 8</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0401-9900</contrib-id><name-alternatives><name xml:lang="en"><surname>Shevchenko</surname><given-names>V. E.</given-names></name><name xml:lang="ru"><surname>Шевченко</surname><given-names>В. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Valeriy Evgenievich Shevchenko</p><p>Bld. 15, 24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>Валерий Евгеньевич Шевченко</p><p>115478 Москва, Каширское шоссе, 24</p></bio><email>vshev2015@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">V.N. Orekhovich Research Institute of Biomedical Chemistry</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научно-исследовательский институт биомедицинской химии им. В.Н. Ореховича»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2021</year></pub-date><volume>8</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>75</fpage><lpage>83</lpage><history><date date-type="received" iso-8601-date="2021-12-18"><day>18</day><month>12</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-12-18"><day>18</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Kushnir T.I., Arnotskaya N.E., Kudryavtsev I.A., Mitrofanov A.A., Bekyashev A.K., Zgoda V.G., Shevchenko V.E.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Кушнир Т.И., Арноцкая Н.Е., Кудрявцев И.А., Митрофанов А.А., Бекяшев А.Х., Згода В.Г., Шевченко В.Е.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Kushnir T.I., Arnotskaya N.E., Kudryavtsev I.A., Mitrofanov A.A., Bekyashev A.K., Zgoda V.G., Shevchenko V.E.</copyright-holder><copyright-holder xml:lang="ru">Кушнир Т.И., Арноцкая Н.Е., Кудрявцев И.А., Митрофанов А.А., Бекяшев А.Х., Згода В.Г., Шевченко В.Е.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://umo.abvpress.ru/jour/article/view/392">https://umo.abvpress.ru/jour/article/view/392</self-uri><abstract xml:lang="en"><p><bold>Introduction</bold>. To a large extent, the resistance of glioblastoma multiforme to genotoxic therapy is associated with a dysregulation of responses to DNA damage and repair. Thus, suppression of DNA repair mechanisms is a priority pathway for increasing the survival rate of glioblastoma multiforme patients. Curcumin enhances the effectiveness of standard chemotherapy drugs, but its effect on DNA repair systems is not well understood.</p><p><bold>The study objective</bold> – to study the molecular mechanisms of curcumin action on excisional DNA repair in U251 glioblastoma multiforme cells.</p><p><bold>Materials and methods</bold>. high-resolution proteomic mass spectrometry, cell technologies.</p><p><bold>Results</bold>. In the proteomes of two types of glioblastoma multiforme cells (control and experiment), a total of 2757 proteins were identified, of which 39 % were differentially expressed. Significant changes have been found in many signaling cascades that play an important role in carcinogenesis.</p><p><bold>Conclusion</bold>. Curcumin suppressed excisional DNA repair by decreasing the expression of determinants APEX1, MSH6, PARP1. PCNA, POLD1, POLE3, RFC2, RPA.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение</bold>. В значительной степени резистентность мультиформной глиобластомы к генотоксической терапии связана с нарушением регуляции реакций на повреждение и репарацию ДНК. Таким образом, подавление механизмов репарации ДНК – приоритетный путь для увеличения выживаемости больных с данной патологией. Куркумин повышает эффективность стандартных химиотерапевтических препаратов, однако его воздействие на системы репарации ДНК недостаточно изучено.</p><p><bold>Цель исследования</bold> – изучение молекулярных механизмов действия куркумина на эксцизионную репарацию ДНК в клетках U251 мультиформной глиобластомы.</p><p><bold>Материалы и методы</bold>. Протеомная масс-спектрометрия высокого разрешения, клеточные технологии.</p><p><bold>Результаты</bold>. В протеомах 2 типов клеток мультиформной глиобластомы (контроля и опыта) в целом идентифицированы 2757 белков, из которых 39 % были дифференциально экспрессированными. Обнаружены значительные изменения во многих сигнальных каскадах, играющих большую роль в канцерогенезе.</p><p><bold>Заключение</bold>. Куркумин супрессирует эксцизионную репарацию ДНК, снижая экспрессию детерминант APEX1, MSH6, PARP1. PCNA, POLD1, POLE3, RFC2 и RPA.</p></trans-abstract><kwd-group xml:lang="en"><kwd>curcumin</kwd><kwd>glioblastoma multiforme</kwd><kwd>curcumin</kwd><kwd>proteome</kwd><kwd>excision DNA repair</kwd><kwd>mass spectrometry</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>мультиформная глиобластома</kwd><kwd>куркумин</kwd><kwd>протеом</kwd><kwd>эксцизионная репарация ДНК</kwd><kwd>масс-спектрометрия</kwd></kwd-group><funding-group><funding-statement xml:lang="en">It is funded under the state budget theme No. 2021-76.</funding-statement><funding-statement xml:lang="ru">Финансируется в рамках госбюджетной темы № 2021-76.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Arvold N.D., Reardon D.A. Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging 2014;9:357–67. DOI: 10.2147/CIA.S44259.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Chinnaiyan P., Won M., Wen P.Y. et al. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neuro Oncol 2018;20:666–73. DOI: 10.1093/neuonc/nox209.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Fabian D., Eibl M.D.P.G.P., Alnahhas I. et al. Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review. Cancers 2019;11:1–12. DOI: 10.3390/cancers11020174.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Kocaadam B., Sanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr 2015;57(13):2889–95. DOI: 10.1080/10408398.2015.1077195.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Kaina B., Christmann M. DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas. DNA Repair (Amst) 2019;78:128–41. DOI: 10.1016/j.dnarep.2019.04.007.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ferri A., Stagni V., Barilà D. et al. Targeting the DNA damage response to overcome cancer drug resistance in glioblastoma. Int J Mol Sci 2020;21(14):4910. DOI: 10.3390/ijms21144910.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Kotha R.R., Luthria D.L. Curcumin: biological, pharmaceutical, nutraceutical, and analytical aspects. Molecules 2019;24(16):2930. DOI: 10.3390/molecules24162930.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Luthra P.M., Lal N. Prospective of curcumin, a pleiotropic signaling molecule from Curcuma longa in the treatment of glioblastoma. Eur J Med Chem 2016;109:23–35. DOI: 10.1016/j.ejmech.2015.11.049.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hosseini A., Hosseinzadeh H. Antidotal or protective effects of Curcuma longa (turmeric) and its active ingredient, curcumin, against natural and chemical toxicities: a review. Biomed Pharmacother 2018;99:411–21. DOI: 10.1016/j.biopha.2018.01.072.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Amalraj A., Pius A., Gopi S. et al. Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives: a review. J Tradit Complement Med 2016;7(2):205–33. DOI: 10.1016/j.jtcme.2016.05.005.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Meng X., Cai J., Liu J. et al. Curcumin increases efficiency of γ-irradiation in gliomas by inhibiting Hedgehog signaling pathway. Cell Cycle 2017;16(12):1181–92. DOI: 10.1080/15384101.2017.1320000.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Park K.S., Yoon S.Y., Park S.H. et al. Antimigration and anti-invasion effects of curcumin via suppression of fascin expression in glioblastoma cells. Brain Tumor Res Treat 2019;7(1):16–24. DOI: 10.14791/btrt.2019.7.e28.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Maiti P., Scott J., Sengupta D. et al. Curcumin and solid lipid curcumin particles induce autophagy, but inhibit mitophagy and the PI3K-Akt/mTOR pathway in cultured glioblastoma cells. Int J Mol Sci 2019;20(2):399. DOI: 10.3390/ijms20020399.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Trotta T., Panaro M.A., Prifti E. et al. Modulation of biological activities in glioblastoma mediated by curcumin. Nutr Cancer 2019;71(8):1241–53. DOI: 10.1080/01635581.2019.1604978.</mixed-citation></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Kushnir T.I., Arnotskaya N.E., Kudryavtsev I.A. et al. The effect of hypoxia on the secretome of human glioblastoma multiforme cells. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2021;8(1):32–40. (In Russ.). DOI: 10.17650/2313-805X-2021-8-1-32-40.</mixed-citation><mixed-citation xml:lang="ru">Кушнир Т.И., Арноцкая Н.Е., Кудрявцев И.А. и др. Влияние гипоксии на секретом клеток мультиформной глиобластомы человека. Успехи молекулярной онкологии 2021;8(1):32–40. DOI: 10.17650/2313-805X-2021-8-1-32-40.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><mixed-citation>Bryukhovetskiy A., Shevchenko V., Kovalev S. et al. To the novel paradigm of proteome-based cell therapy of tumors: through comparative proteome mapping of tumor stem cells and tissue-specific stem cells of humans. Cell Transplant 2014;23(1):151–70. DOI: 10.3727/096368914X684907.</mixed-citation></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Gromova O.A., Torshin Y.U., Zgoda V.G. et al. An analysis of the peptide composition of a “light” peptide fraction of Cerebrolysin. S.S. Korsakov Journal of Neurology and Psychiatry 2019;119(8):75–83. (In Russ.). DOI: 10.17116/jnevro201911908175.</mixed-citation><mixed-citation xml:lang="ru">Громова О.А., Торшин И.Ю., Згода В.Г. и др. Комплексный протеомный анализ «легкой» пептидной фракции препарата церебролизин. Журнал неврологии и психиатрии им. С.С. Корсакова 2019;119(8):75–83 DOI: 10.17116/jnevro201911908175.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><mixed-citation>Cox J., Hein M.Y., Luber C.A. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics 2014;13(9):2513–26. DOI: 10.1074/mcp.M113.031591.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Huang D.W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009;37(1):1–13. DOI: 10.1093/nar/gkn923.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Lee S.Y. Temozolomide resistance in glioblastoma multiforme. Genes Dis 2016;3:198–210. DOI: 10.1016/j.gendis.2016.04.007.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Fulton B., Short S.C., James A. et al. PARADIGM-2: two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clin Transl Radiat Oncol 2017;8:12–6. DOI: 10.1016/j.ctro.2017.11.003.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Xu T., Guo P., He Y. et al. Application of curcumin and its derivatives in tumor multidrug resistance Phytother Res 2020;34(10):2438–58. DOI: 10.1002/ptr.6694.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Alexandru O., Georgescu A.M., Ene L. et al. The effect of curcumin on lowpassage glioblastoma cells in vitro. J Cancer Res Ther 2016;12(2):1025–32. DOI: 10.4103/0973-1482.167609.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Tomeh M.A., Hadianamrei R., Zhao X. A review of curcumin and its derivatives as anticancer agents. Int J Mol Sci 2019;20(5):1033. DOI: 10.3390/ijms20051033.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Rodriguez G.A., Shah A.H., Gersey Z.C. et al. Investigating the therapeutic role and molecular biology of curcumin as a treatment for glioblastoma. Ther Adv Med Oncol 2016;8(4):248–60. DOI: 10.1177/1758834016643518.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Stupp R., Mason W.P., van den Bent M.J. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987–96. DOI: 10.1056/NEJMoa043330.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Nakada M., Furuta T., Hayashi Y. et al. The strategy for enhancing temozolomide against malignant glioma. Front Oncol 2012;2:98. DOI: 10.3389/fonc.2012.00098.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Atkins R.J., Ng W., Stylli S.S. et al. Repair mechanisms help glioblastoma resist treatment. J Clin Neurosci 2015;22(1):14–20. DOI: 10.1016/j.jocn.2014.09.003.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Gu Y., Parker A., Wilson T.M. et al. Human MutY homolog, a DNA glycosylase involved in base excision repair, physically and functionally interacts with mismatch repair proteins humanMutS homolog 2/ humanMutS homolog 6. J Biol Chem 2002;277(13):11135–42. DOI: 10.1074/jbc.M108618200.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Xie C., Sheng H., Zhang N. et al. Association of MSH6 mutation with glioma susceptibility, drug resistance and progression. Mol Clin Oncol 2016;5(2):236–40. DOI: 10.3892/mco.2016.907.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Pluciennik A., Modrich P. Protein roadblocks and helix discontinuities are barriers to the initiation of mismatch repair. Proc Natl Acad Sci USA 2007;104(31):12709–13. DOI: 10.1073/pnas.0705129104.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Longley M.J., Pierce A.J., Modrich P. DNA polymerase delta is required for human mismatch repair in vitro. J Biol Chem 1997;272(16):10917–21. DOI: 10.1074/jbc.272.16.10917.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006;7(5):335–46. DOI: 10.1038/nrm1907.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Jiapaer S., Furuta T., Tanaka S. et al. Potential strategies overcoming the temozolomide resistance for glioblastoma. Neurol Med Chir (Tokyo) 2018;58(10):405–21. DOI: 10.2176/nmc.ra.2018-0141.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Li M., Wilson D.M. Human apurinic/ apyrimidinic endonuclease. Antioxid Redox Signal 2014;20(4):678–707. DOI: 10.1089/ars.2013.5492.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Erasimus H., Gobin M., Niclou S. et al. DNA repair mechanisms and their clinical impact in glioblastoma. Mutat Res Rev Mutat Res 2016;769:19–35. DOI: 10.1016/j.mrrev.2016.05.005.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Matsumoto Y., Kim К., Hurwitz J. et al. Reconstitution of proliferating cell nuclear antigen-dependent repair of apurinic/ apyrimidinic sites with purified human proteins. J Biol Chem 1999;274(47):33703–8. DOI: 10.1074/jbc.274.47.33703.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Chen C.C., Juan C.W., Chen K.Y. et al. Upregulation of RPA2 promotes NF-κB activation in breast cancer by relieving the antagonistic function of menin on NF-κB-regulated transcription. Carcinogenesis 2017;38(2):196–206. DOI: 10.1093/carcin/bgw123.</mixed-citation></ref></ref-list></back></article>
